Jan 17, 2021 (Heraldkeepers) -- Tissue TransglutaminaseTest Market Scenario
Tissue transglutaminase (TG) test is used for the diagnosis of certain autoimmune diseases, which is mostly limited to celiac disease. In celiac disease, gluten (a protein found in wheat, barley, rye, and oats) is seen as a foreign invader and is attacked by the immune system, followed by the production of antibodies directed against the enzyme Tissue Transglutaminase (TG) (a calcium dependent proteolysis restricting enzyme), which is normally present in intestines.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/824
Immunoglobulin A (IgA) and immunoglobulin G (IgG) are the antibodies responsible for the autoimmune responses. The IgA form of TG antibody is more frequently exploited for the diagnosis of celiac disease. This is because it is synthesized in the small intestine where gluten causes inflammation and irritation in sensitive people. Its application in testing is marked when patient is incapable to produce normal IgA as it is less specific to celiac disease.
The market is expected to grow at a CAGR of ~17.5% during the forecast period of 2018 to 2023. The major factor that propels the global tissue transglutaminase test market is the increasing prevalence of celiac disease and an increasing geriatric population. False positive diagnosis in geriatric population restrain the growth of the market.
Tissue TransglutaminaseTest Market Regional Analysis
The tissue transglutaminase test market is segmented into the Americas, Europe, Asia-Pacific and Middle East & Africa.
The Americas account for a significant market share owing to high usage of medications and high expenditure on the health care facilities and products. Moreover, the fast uptake of new technological advancements in the United States drive the global tissue transglutaminase test market. Additionally, the concentration of major research companies and research organizations in the developed countries of this region boost the market growth.
Europe is the second largest market in the world. This is because of high income and healthcare penetration in the region.
Asia Pacific region is expected to grow speedily. Some of the countries in this region, namely India and China are expected to lead this market due to fast growing healthcare sector during the forecast period.
Gulf nations such as Saudi Arabia and the UAE are projected to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and poor healthcare development. Also, difficult political conditions may hinder the growth.
Global Tissue TransglutaminaseTest Market Competitive Landscape
The global tissue transglutaminase test market is observed to be growing upwards due to the technological advancements of key players like Quest Diagnostics Incorporated., SQI Diagnostics, Trinity Biotech, ZEDIRA GmbH, Demeditec Diagnostics GmbH, ARUP Laboratories, Cell Science Systems, and Bio-Rad Laboratories, Inc., Pfizer Inc., Amgen Inc., Ajinomoto Co, Inc., Yiming Biological Products Co., Ltd., Micro-Tech Foods Ingredients, Inc, Kinry Food Ingredients Co., Ltd., Nanning Pangbo Biological Engineering Co., Ltd., and BioRap Technologies Ltd.
The well-established market players are involved in strategic collaborations and new product launches to gain an edge over other competitors in this market.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/tissue-transglutaminase-test-market-824
Some of the key players in this market are Quest Diagnostics Incorporated., SQI Diagnostics, Trinity Biotech, Zedira GmbH, Demeditec Diagnostics GmbH, ARUP Laboratories, Cell Science Systems, and Bio-Rad Laboratories, Inc., Pfizer Inc., Amgen Inc., Ajinomoto Co, Inc., Yiming Biological Products Co., Ltd., Micro-Tech Foods Ingredients, Inc, Kinry Food Ingredients Co., Ltd., Nanning Pangbo Biological Engineering Co., Ltd. and BioRap Technologies Ltd.
Browse More Related Reports at:
Alzheimer's disease diagnostic market is projected to reach a valuation of approximately USD 12 BN by 2022